Evolus (EOLS) Expected to Post Earnings on Wednesday

Evolus (NASDAQ:EOLS) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.05) per share and revenue of $77.58 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $7.37 on Wednesday. The stock’s 50-day simple moving average is $8.03 and its two-hundred day simple moving average is $6.23. Evolus has a 52-week low of $3.86 and a 52-week high of $9.31.

Analysts Set New Price Targets

Several research firms have recently commented on EOLS. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Tuesday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Evolus in a report on Friday, September 11th. Finally, Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.50.

Insider Buying and Selling

In other Evolus news, insider David Moatazedi sold 105,108 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the completion of the transaction, the insider owned 499,592 shares in the company, valued at $4,516,311.68. This trade represents a 17.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.00% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.